Volume 39 Issue 7
Jul.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Nanjing University of traditional Chinese Medicine  > 2023  >  39(7): 613-617
LIU Yan-dong, DENG Qiang, LI Zhong-feng, PENG Ran-dong, WANG Yu-rong, YANG Zhen-yuan, GUO Tie-feng, LUO Lin-zhao. Exploring Effects of Irisin on Musculoskeletal Decay Based on Equal Emphasis on Sinews and Bones and Same Treatment for Different Diseases Theories[J]. Journal of Nanjing University of traditional Chinese Medicine, 2023, 39(7): 613-617. doi: 10.14148/j.issn.1672-0482.2023.0613
Citation: LIU Yan-dong, DENG Qiang, LI Zhong-feng, PENG Ran-dong, WANG Yu-rong, YANG Zhen-yuan, GUO Tie-feng, LUO Lin-zhao. Exploring Effects of Irisin on Musculoskeletal Decay Based on Equal Emphasis on Sinews and Bones and Same Treatment for Different Diseases Theories[J]. Journal of Nanjing University of traditional Chinese Medicine, 2023, 39(7): 613-617. doi: 10.14148/j.issn.1672-0482.2023.0613
shu

Exploring Effects of Irisin on Musculoskeletal Decay Based on Equal Emphasis on Sinews and Bones and Same Treatment for Different Diseases Theories

doi: 10.14148/j.issn.1672-0482.2023.0613
  • 1.

    Clinical College of Traditional Chinese Medicine, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China

  • 2.

    Spinal Disease Diagnosis and Treatment Center, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, China

  • Received Date: 2023-05-13
    Available Online: 2023-07-15
    Abstract
  • Skeleton and skeletal muscle cross talk with each other through various channels, and together form the largest biological movement tissue of the body, the musculoskeletal system. Irisin is a kind of hormone-like muscle factor mediated by exercise, which has dual functions of simultaneously regulating muscle regeneration and bone homeostasis. Based on the theories of "equal emphasis on sinews and bones" and "same treatment for different diseases ", this study explores the dual therapeutic effects of irisin on musculoskeletal decay lesions from the perspectives of traditional Chinese medicine and Western medicine, in order to provide new directions for basic research and clinical prevention and treatment of muscle and bone comorbidities.

     

    • FullText(HTML)
  • loading
    • References(44)
  • [1]
    LASKOU F, FUGGLE NR, PATEL HP, et al. Associations of osteoporosis and sarcopenia with frailty and multimorbidity among participants of the Hertfordshire Cohort Study[J]. J Cachexia Sarcopenia Muscle, 2022, 13(1): 220-229. doi: 10.1002/jcsm.12870
    [2]
    YU C, DU YJ, PENG Z, et al. Research advances in crosstalk between muscle and bone in osteosarcopenia[J]. Exp Ther Med, 2023, 25(4): 189. doi: 10.3892/etm.2023.11888
    [3]
    BOUTIN RD, LENCHIK L. Value-added opportunistic CT: Insights into osteoporosis and sarcopenia[J]. AJR Am J Roentgenol, 2020, 215(3): 582-594. doi: 10.2214/AJR.20.22874
    [4]
    巢元方. 诸病源候论[M]. 北京: 中国中医药出版社, 2011: 278-281.

    CHAO YF. The Theory of Various Diseases and Their Origins[M]. Beijing: China press of traditional Chinese medicine, 2011: 278-281.
    [5]
    秦大平, 张晓刚, 宋敏, 等. 从筋骨并重理论探讨肌少症与骨质疏松症的中医药防治策略[J]. 中华中医药杂志, 2019, 34(9): 4364-4369. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201909124.htm

    QIN DP, ZHANG XG, SONG M, et al. Discussion on the prevention and treatment strategy of sarcopenia and osteoporosis with traditional Chinese medicine based on the theory of muscles and bones[J]. China J Tradit Chin Med Pharm, 2019, 34(9): 4364-4369. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201909124.htm
    [6]
    LARA-CASTILLO N, JOHNSON ML. Bone-muscle mutual interactions[J]. Curr Osteoporos Rep, 2020, 18(4): 408-421. doi: 10.1007/s11914-020-00602-6
    [7]
    ZHOU BN, ZHANG Q, LIN XY, et al. The roles of sclerostin and irisin on bone and muscle of orchiectomized rats[J]. BMC Musculoskelet Disord, 2022, 23(1): 1049. doi: 10.1186/s12891-022-05982-7
    [8]
    LIU SQ, CUI FQ, NING KT, et al. Role of irisin in physiology and pathology[J]. Front Endocrinol, 2022, 13: 962968. doi: 10.3389/fendo.2022.962968
    [9]
    黄元御. 四圣心源[M]. 北京: 中国科学技术出版社, 2019: 139-143.

    HUANG YY. The Four Sages Study[M]. Beijing: China science and technology press, 2019: 139-143.
    [10]
    张啸宇, 李敬池, 王楠, 等. "筋骨并重"理论指导下腰背肌锻炼降低PTED术后邻椎病风险力学机制的研究[J]. 中国中西医结合杂志, 2021, 41(6): 695-700. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ202106014.htm

    ZHANG XY, LI JC, WANG N, et al. Study on the biomechanical mechanism of paraspinal muscles exercise to reduce the risk of adjacent segment disease after percutaneous transforaminal endoscopic discectomy guided by "paying equal attention to sinew and bone"[J]. Chin J Integr Tradit West Med, 2021, 41(6): 695-700. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ202106014.htm
    [11]
    刘斌, 苏晓川, 滕军燕. 中西医结合治疗骨折原则的新启示[J]. 中华中医药杂志, 2020, 35(10): 4804-4807. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202010010.htm

    LIU B, SU XC, TENG JY. New enlightenment on the rule of integration of traditional Chinese and western medicine in the treatment of fractures[J]. China J Tradit Chin Med Pharm, 2020, 35(10): 4804-4807. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202010010.htm
    [12]
    吴谦. 医宗金鉴[M]. 北京: 中国中医药出版社, 1994: 355-369.

    WU Q. The Golden Mirror of Medicine[M]. Beijing: China press of traditional Chinese medicine, 1994: 355-369.
    [13]
    王国军. "筋骨并重"理念在骨科疾病中的应用[J]. 江苏中医药, 2019, 51(11): 41-44. doi: 10.3969/j.issn.1672-397X.2019.11.015

    WANG GJ. The application of "equal value of both tendon and bone" in the treatment to orthopaedics diseases[J]. Jiangsu J Tradit Chin Med, 2019, 51(11): 41-44. doi: 10.3969/j.issn.1672-397X.2019.11.015
    [14]
    黄帝内经灵枢[M]. 北京: 人民卫生出版社, 2015: 151-152.

    The Yellow Emperor's Canon of Internal Medicine: Lingshu[M] Beijing: People's medical publishing house, 2015: 151-152.
    [15]
    路翀, 郑浩, 杨鸫祥, 等. 基于"脾肾相关"理论探讨鸢尾素在肌少-骨质疏松症中的作用机制[J]. 中国骨质疏松杂志, 2022, 28(10): 1507-1513. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS202210019.htm

    LU C, ZHENG H, YANG DX, et al. Exploration of the mechanism of irisin in sarcopenia-osteopenia based on the spleen-kidney correlation theory[J]. Chin J Osteoporos, 2022, 28(10): 1507-1513. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS202210019.htm
    [16]
    YANG JY, JIANG T, XU GM, et al. Bibliometrics analysis and visualization of sarcopenia associated with osteoporosis from 2000 to 2022[J]. J Pain Res, 2023, 16: 821-837. doi: 10.2147/JPR.S403648
    [17]
    SALAMANNA F, CONTARTESE D, RUFFILLI A, et al. Sharing circulating micro-RNAs between osteoporosis and sarcopenia: A systematic review[J]. Life, 2023, 13(3): 602. doi: 10.3390/life13030602
    [18]
    PICKERING ME. Cross-talks between the cardiovascular disease-sarcopenia-osteoporosis triad and magnesium in humans[J]. Int J Mol Sci, 2021, 22(16): 9102. doi: 10.3390/ijms22169102
    [19]
    桑继亮, 杨岩冰, 马江涛, 等. 基于PI3K/Akt/FoxO3a信号通路探讨壮骨止痛胶囊防治肌少-骨质疏松症的作用机制[J]. 中医药信息, 2022, 39(10): 19-27. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXN202210004.htm

    SANG JL, YANG YB, MA JT, et al. Mechanism of Zhuanggu Zhitong capsule in preventing and treating osteosarcopenia based on PI3K/akt/FoxO3a signaling pathway[J]. Inf Tradit Chin Med, 2022, 39(10): 19-27. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXN202210004.htm
    [20]
    BAO JF, SHE QY, HU PP, et al. Irisin, a fascinating field in our times[J]. Trends Endocrinol Metab, 2022, 33(9): 601-613. doi: 10.1016/j.tem.2022.06.003
    [21]
    MAAK S, NORHEIM F, DREVON CA, et al. Progress and challenges in the biology of FNDC5 and irisin[J]. Endocr Rev, 2021, 42(4): 436-456. doi: 10.1210/endrev/bnab003
    [22]
    POLYZOS SA, ANASTASILAKIS AD, EFSTATHIADOU ZA, et al. Irisin in metabolic diseases[J]. Endocrine, 2018, 59(2): 260-274. doi: 10.1007/s12020-017-1476-1
    [23]
    LIU JS, QI BT, GAN L, et al. A bibliometric analysis of the literature on irisin from 2012-2021[J]. Int J Environ Res Public Heath, 2022, 19(10): 6153. doi: 10.3390/ijerph19106153
    [24]
    KORTA P, POCHEC EW, MAZUR-BIAŁYA. Irisin as a multifunctional protein: Implications for health and certain diseases[J]. Medicina, 2019, 55(8): 485. doi: 10.3390/medicina55080485
    [25]
    FLORI L, TESTAI L, CALDERONE V. The irisin system: From biological roles to pharmacological and nutraceutical perspectives[J]. Life Sci, 2021, 267: 118954. doi: 10.1016/j.lfs.2020.118954
    [26]
    ZHU X, LI X, WANG X, et al. Irisin deficiency disturbs bone metabolism[J]. J Cell Physiol. 2021, 236(1): 664-676. doi: 10.1002/jcp.29894
    [27]
    CHANG JS, KIM TH, NGUYEN TT, et al. Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study[J]. Geriatr Gerontol Int, 2017, 17(11): 2266-2273. doi: 10.1111/ggi.13030
    [28]
    WU YX, WU YX, YU J, et al. Irisin ameliorates D-galactose-induced skeletal muscle fibrosis via the PI3K/Akt pathway[J]. Eur J Pharmacol, 2023, 939: 175476. doi: 10.1016/j.ejphar.2022.175476
    [29]
    WANG YW, GU YQ, HUANG J, et al. Serum vitamin D status and circulating irisin levels in older adults with sarcopenia[J]. Front Nutr, 2022, 9: 1051870. doi: 10.3389/fnut.2022.1051870
    [30]
    KONISHI M, ISHIDA J, SAITO M, et al. Irisin—a myokine potentially bridging muscle and fat tissue in cachexia[J]. J Cachexia Sarcopenia Muscle, 2015, 6(4): 396-397. doi: 10.1002/jcsm.12085
    [31]
    GUO M, YAO J, LI J, et al. Irisin ameliorates age-associated sarcopenia and metabolic dysfunction[J]. J Cachexia Sarcopenia Muscle, 2023, 14(1): 391-405. doi: 10.1002/jcsm.13141
    [32]
    D'AMURI A, SANZ JM, LAZZER S, et al. Irisin attenuates muscle impairment during bed rest through muscle-adipose tissue crosstalk[J]. Biology, 2022, 11(7): 999. doi: 10.3390/biology11070999
    [33]
    WU YX, WU YX, YU J, et al. Irisin ameliorates D-galactose-induced skeletal muscle fibrosis via the PI3K/Akt pathway[J]. Eur J Pharmacol, 2023, 939: 175476. doi: 10.1016/j.ejphar.2022.175476
    [34]
    TIANO JP, SPRINGER DA, RANE SG. SMAD3 negatively regulates serum irisin and skeletal muscle FNDC5 and peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) during exercise[J]. J Biol Chem. 2015, 290(12): 7671-84. doi: 10.1074/jbc.M114.617399
    [35]
    COLAIANNI G, STORLINO G, SANESI L, et al. Myokines and osteokines in the pathogenesis of muscle and bone diseases[J]. Curr Osteoporos Rep, 2020, 18(4): 401-407. doi: 10.1007/s11914-020-00600-8
    [36]
    XUE Y, HU SH, CHEN CC, et al. Myokine Irisin promotes osteogenesis by activating BMP/SMAD signaling via αV integrin and regulates bone mass in mice[J]. Int J Biol Sci, 2022, 18(2): 572-584. doi: 10.7150/ijbs.63505
    [37]
    COLAIANNI G, CUSCITO C, MONGELLI T, et al. The myokine irisin increases cortical bone mass[J]. Proc Natl Acad Sci USA, 2015, 112(39): 12157-12162. doi: 10.1073/pnas.1516622112
    [38]
    ALBRECHT E, NORHEIM F, THIEDE B, et al. Irisin—a myth rather than an exercise-inducible myokine[J]. Sci Rep, 2015, 5: 8889. doi: 10.1038/srep08889
    [39]
    ZERLOTIN R, ORANGER A, PIGNATARO P, et al. Irisin and secondary osteoporosis in humans[J]. Int J Mol Sci, 2022, 23(2): 690. doi: 10.3390/ijms23020690
    [40]
    XU LL, SHEN LY, YU XL, et al. Effects of irisin on osteoblast apoptosis and osteoporosis in postmenopausal osteoporosis rats through upregulating Nrf2 and inhibiting NLRP3 inflammasome[J]. Exp Ther Med, 2020, 19(2): 1084-1090.
    [41]
    BEHERA J, ISON J, VOOR MJ, et al. Exercise-linked skeletal irisin ameliorates diabetes-associated osteoporosis by inhibiting the oxidative damage-dependent miR-150-FNDC5/pyroptosis axis[J]. Diabetes, 2022, 71(12): 2777-2792. doi: 10.2337/db21-0573
    [42]
    MA YX, QIAO XY, ZENG RJ, et al. Irisin promotes proliferation but inhibits differentiation in osteoclast precursor cells[J]. FASEB J, 2018, 32(11): 5813-5823. doi: 10.1096/fj.201700983RR
    [43]
    ESTELL EG, LE PT, VEGTING Y, et al. Irisin directly stimulates osteoclastogenesis and bone resorption in vitro and in vivo[J]. Elife, 2020, 9: e58172. doi: 10.7554/eLife.58172
    [44]
    祁亮, 莫亮, 卫杨文祥, 等. 骨质疏松症和动脉粥样硬化机制及"异病同治"分析[J]. 中国骨质疏松杂志, 2023, 29(2): 215-220, 231. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS202302012.htm

    QI L, MO L, WEI YWX, et al. Analysis of mechanisms between osteoporosis and atherosclerosis with concept of "simultaneous treatment of different diseases"[J]. Chin J Osteoporos, 2023, 29(2): 215-220, 231. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS202302012.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (86) PDF downloads(12) Cited by()
    Proportional views
    Related

    Copyright © Journal of Nanjing University of traditional Chinese Medicine

    Sponsored by：Nanjing University of traditional Chinese MedicineAddress：No.138 xianlin Avenue, Qixia District, Nanjing cityChina Pos：210023

    Tel：025-85811935Email：xb@njucm.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return